3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other
2
Head & Neck
2
Conditions
Lymphoma
3
Stomatitis
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Mucositis
2
Mouth Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Small Cell
2
Brain Neoplasms
2
Spinal Cord Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
5
Cisplatin
3
RRx-001
2
Injections
2
trastuzumab deruxtecan
1
gluconic acid
1
belinostat
1
Zinc
1
Taxes
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Pemetrexed
1
Paclitaxel
1
Omeprazole
1
Nivolumab
1
Indomethacin
1
IRX 2
1
Fluorouracil
1
Drug Therapy
1
Cyclophosphamide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mouth Neoplasms
×
RRx-001
×
Clear all
NCT05966194
2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2
Recruiting
216 enrolled
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts